What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially announce and provide investors with Pfizer Inc.'s financial results for the third quarter of 2004, as disclosed in a press release.

Where can I find the actual third-quarter financial results?

The actual third-quarter financial results are detailed in the press release dated October 20, 2004, which is furnished as Exhibit 99 to this 8-K filing and incorporated by reference.

Does this filing contain detailed financial figures for Q3 2004?

No, the 8-K filing itself does not contain the detailed financial figures. It serves as a notification that the results have been released and directs investors to the accompanying press release (Exhibit 99) for those specifics.

PFE 8-K: Earnings & Results

Summary

Pfizer Inc. (PFE) filed an 8-K report on October 20, 2004, to announce its financial results for the third quarter of 2004. The primary purpose of this filing is to provide investors with the company's performance during the specified quarter, disseminated through a press release. This report serves as an official channel for disclosing material financial information as required by the SEC.

Key Highlights

1Pfizer Inc. announced its financial results for the third quarter of 2004.
2The announcement was made via a press release filed as Exhibit 99 to the 8-K.
3The report date and the earliest event reported are both October 20, 2004.
4The filing follows SEC regulations for reporting material financial events.
5No specific financial figures or operational details are included directly in the 8-K text, only a reference to the attached press release.
6The press release, which contains the actual Q3 2004 financial results, is incorporated by reference.

PFIZER INC 8-K Report, Financial Results (Oct 20, 2004)

Summary

Key Highlights

Frequently Asked Questions